Head-to-head evidence
Ebronucimab vs Ongericimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Ebronucimab
Developed by Akeso
NCT05255094 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 464 participants, providing a strong experimental design. However, its primary endpoint was a laboratory lipid measure rather than a hard clinical outcome, and the registry does not report whether the comparison was favorable or statistically significant.
Ongericimab · Junshida
Developed by Shanghai Junshi Bioscience
NCT04781114 · Phase 3 · completed
This large, randomized, placebo-controlled trial kept participants, care providers, investigators and outcome assessors blind to treatment assignment. Its primary endpoint was clearly met: both ongericimab dose regimens produced large, statistically significant reductions in LDL cholesterol versus placebo.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ebronucimab's landscape · Ongericimab's landscape